NO315895B1 - Farmasöytisk preparat for kontroll av cellesyklusutvikling, fremstilling avdette for regulering av cellesyklusutvikling i en celle sommangler et funksjonelt retinoblastomtumorsuppressorprotein, samt fremgangsmåte forkontroll av cellesyklusutv - Google Patents

Farmasöytisk preparat for kontroll av cellesyklusutvikling, fremstilling avdette for regulering av cellesyklusutvikling i en celle sommangler et funksjonelt retinoblastomtumorsuppressorprotein, samt fremgangsmåte forkontroll av cellesyklusutv Download PDF

Info

Publication number: NO315895B1
Authority: NO; Norway
Prior art keywords: cells; cell; cell cycle; protein; injected
Prior art date: 1991-10-17

Application number

NO19941377A

Other languages

English (en)

Norwegian (no)

Other versions

NO941377L (no

NO941377D0 (no

Inventor

Wen-Hwa Lee

Eva Y H P Lee

David W Goodrich

Nang-Ping Wang

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-17

Filing date

1994-04-15

Publication date

2003-11-10

1994-04-15 Application filed by Univ California filed Critical Univ California

1994-04-15 Publication of NO941377D0 publication Critical patent/NO941377D0/no

1994-06-10 Publication of NO941377L publication Critical patent/NO941377L/no

2003-11-10 Publication of NO315895B1 publication Critical patent/NO315895B1/no

Links

230000022131 cell cycle Effects 0.000 title claims abstract description 45
238000000034 method Methods 0.000 title claims abstract description 17
230000001105 regulatory effect Effects 0.000 title claims abstract description 11
230000001276 controlling effect Effects 0.000 title claims abstract description 7
238000011161 development Methods 0.000 title claims description 34
238000002360 preparation method Methods 0.000 title claims description 23
201000000582 Retinoblastoma Diseases 0.000 title claims description 10
239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
108010040002 Tumor Suppressor Proteins Proteins 0.000 title description 3
102000001742 Tumor Suppressor Proteins Human genes 0.000 title description 3
239000000225 tumor suppressor protein Substances 0.000 title description 3
108090000623 proteins and genes Proteins 0.000 claims abstract description 53
102000004169 proteins and genes Human genes 0.000 claims abstract description 47
239000012634 fragment Substances 0.000 claims abstract description 20
230000016507 interphase Effects 0.000 claims abstract description 10
210000004027 cell Anatomy 0.000 claims description 193
150000001413 amino acids Chemical class 0.000 claims description 17
238000000338 in vitro Methods 0.000 claims description 7
230000007704 transition Effects 0.000 claims description 5
108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 4
102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 4
210000004899 c-terminal region Anatomy 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims 2
210000004900 c-terminal fragment Anatomy 0.000 claims 1
230000006369 cell cycle progression Effects 0.000 abstract description 19
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 18
239000000203 mixture Substances 0.000 abstract description 4
230000035899 viability Effects 0.000 abstract description 3
230000002708 enhancing effect Effects 0.000 abstract 1
108050002653 Retinoblastoma protein Proteins 0.000 description 69
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 59
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 58
229950004398 broxuridine Drugs 0.000 description 58
238000002347 injection Methods 0.000 description 47
239000007924 injection Substances 0.000 description 47
235000018102 proteins Nutrition 0.000 description 42
230000018199 S phase Effects 0.000 description 33
238000011282 treatment Methods 0.000 description 33
230000000694 effects Effects 0.000 description 28
230000018109 developmental process Effects 0.000 description 27
MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 25
230000010190 G1 phase Effects 0.000 description 19
AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 19
KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 16
238000010348 incorporation Methods 0.000 description 16
229950006344 nocodazole Drugs 0.000 description 16
230000027455 binding Effects 0.000 description 15
230000002401 inhibitory effect Effects 0.000 description 15
238000002372 labelling Methods 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 12
230000001360 synchronised effect Effects 0.000 description 12
208000005623 Carcinogenesis Diseases 0.000 description 11
XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 11
NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 11
SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 11
230000036952 cancer formation Effects 0.000 description 11
231100000504 carcinogenesis Toxicity 0.000 description 11
230000006870 function Effects 0.000 description 11
230000026731 phosphorylation Effects 0.000 description 11
238000006366 phosphorylation reaction Methods 0.000 description 11
239000004473 Threonine Substances 0.000 description 10
230000006820 DNA synthesis Effects 0.000 description 9
239000000427 antigen Substances 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
230000001413 cellular effect Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 8
238000011534 incubation Methods 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
238000000520 microinjection Methods 0.000 description 8
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 8
ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
230000014509 gene expression Effects 0.000 description 7
230000011278 mitosis Effects 0.000 description 7
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
238000010186 staining Methods 0.000 description 7
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
235000018417 cysteine Nutrition 0.000 description 6
229960001330 hydroxycarbamide Drugs 0.000 description 6
238000012744 immunostaining Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
230000004543 DNA replication Effects 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
108010090804 Streptavidin Proteins 0.000 description 5
235000003704 aspartic acid Nutrition 0.000 description 5
230000008901 benefit Effects 0.000 description 5
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
201000008968 osteosarcoma Diseases 0.000 description 5
238000005406 washing Methods 0.000 description 5
239000004475 Arginine Substances 0.000 description 4
CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
108010033040 Histones Proteins 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
235000013922 glutamic acid Nutrition 0.000 description 4
239000004220 glutamic acid Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000035772 mutation Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
230000009466 transformation Effects 0.000 description 4
OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N Histidine Chemical compound OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
108700025701 Retinoblastoma Genes Proteins 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000025084 cell cycle arrest Effects 0.000 description 3
230000011712 cell development Effects 0.000 description 3
230000009931 harmful effect Effects 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
239000003550 marker Substances 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000002250 progressing effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000004474 valine Substances 0.000 description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
238000012756 BrdU staining Methods 0.000 description 2
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
206010067482 No adverse event Diseases 0.000 description 2
108010089430 Phosphoproteins Proteins 0.000 description 2
102000007982 Phosphoproteins Human genes 0.000 description 2
101150020201 RB gene Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000006951 hyperphosphorylation Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000000394 mitotic effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000022983 regulation of cell cycle Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
101800001415 Bri23 peptide Proteins 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
101800000655 C-terminal peptide Proteins 0.000 description 1
101150012716 CDK1 gene Proteins 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
230000010337 G2 phase Effects 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
101710150114 Protein rep Proteins 0.000 description 1
101710152114 Replication protein Proteins 0.000 description 1
101100508744 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sal3 gene Proteins 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
-1 and Y Chemical compound 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000010370 cell cloning Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
230000009028 cell transition Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000010448 genetic screening Methods 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000036456 mitotic arrest Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000016853 telophase Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)
Cosmetics (AREA)

NO19941377A 1991-10-17 1994-04-15 Farmasöytisk preparat for kontroll av cellesyklusutvikling, fremstilling avdette for regulering av cellesyklusutvikling i en celle sommangler et funksjonelt retinoblastomtumorsuppressorprotein, samt fremgangsmåte forkontroll av cellesyklusutv NO315895B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77851091A	1991-10-17	1991-10-17
PCT/US1992/008918 WO1993008267A1 (en)	1991-10-17	1992-10-16	Cell cycle controlling compositions and methods of using same

Publications (3)

Publication Number	Publication Date
NO941377D0 NO941377D0 (no)	1994-04-15
NO941377L NO941377L (no)	1994-06-10
NO315895B1 true NO315895B1 (no)	2003-11-10

Family

ID=25113590

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19941377A NO315895B1 (no)	1991-10-17	1994-04-15	Farmasöytisk preparat for kontroll av cellesyklusutvikling, fremstilling avdette for regulering av cellesyklusutvikling i en celle sommangler et funksjonelt retinoblastomtumorsuppressorprotein, samt fremgangsmåte forkontroll av cellesyklusutv

Country Status (11)

Country	Link
EP (1)	EP0610420B1 (de)
JP (2)	JP3450006B2 (de)
KR (1)	KR100279797B1 (de)
AT (1)	ATE191928T1 (de)
AU (1)	AU679431B2 (de)
CA (1)	CA2120353C (de)
DE (1)	DE69230943T2 (de)
ES (1)	ES2148181T3 (de)
NO (1)	NO315895B1 (de)
TW (1)	TW346397B (de)
WO (1)	WO1993008267A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0666312A1 (de) *	1994-02-08	1995-08-09	Wolfgang A. Renner	Verfahren zur Förderung des Wachstums von Säugetierzellen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1341576C (en) *	1986-08-11	2008-07-08	Thaddeus P. Dryja	Diagnosis of retinoblastoma
US4942123A (en)	1987-09-17	1990-07-17	The Regents Of The University Of California	ppRB110 -phosphoprotein the retinoblastoma susceptibility gene product
EP0398955B1 (de) *	1988-01-21	1998-07-08	MASSACHUSETTS EYE & EAR INFIRMARY	Diagnose von retinoblastoma
WO1990005180A1 (en)	1988-10-31	1990-05-17	The Regents Of The University Of California	Products and methods for controlling the suppression of the neoplastic phenotype
ZA909755B (en) *	1989-12-07	1991-09-25	Res Dev Foundation	Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product

1992
- 1992-04-17 TW TW081103034A patent/TW346397B/zh not_active IP Right Cessation
- 1992-10-16 ES ES92924108T patent/ES2148181T3/es not_active Expired - Lifetime
- 1992-10-16 AT AT92924108T patent/ATE191928T1/de not_active IP Right Cessation
- 1992-10-16 AU AU30546/92A patent/AU679431B2/en not_active Ceased
- 1992-10-16 KR KR1019940701258A patent/KR100279797B1/ko not_active Expired - Fee Related
- 1992-10-16 DE DE69230943T patent/DE69230943T2/de not_active Expired - Fee Related
- 1992-10-16 CA CA002120353A patent/CA2120353C/en not_active Expired - Fee Related
- 1992-10-16 WO PCT/US1992/008918 patent/WO1993008267A1/en not_active Ceased
- 1992-10-16 JP JP50786393A patent/JP3450006B2/ja not_active Expired - Fee Related
- 1992-10-16 EP EP92924108A patent/EP0610420B1/de not_active Expired - Lifetime
1994
- 1994-04-15 NO NO19941377A patent/NO315895B1/no unknown
2003
- 2003-04-04 JP JP2003102318A patent/JP2003277290A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
TW346397B (en)	1998-12-01
JPH07504805A (ja)	1995-06-01
CA2120353C (en)	2008-04-29
JP3450006B2 (ja)	2003-09-22
KR100279797B1 (ko)	2001-04-02
JP2003277290A (ja)	2003-10-02
NO941377L (no)	1994-06-10
NO941377D0 (no)	1994-04-15
ES2148181T3 (es)	2000-10-16
EP0610420B1 (de)	2000-04-19
AU3054692A (en)	1993-05-21
DE69230943T2 (de)	2000-11-30
WO1993008267A1 (en)	1993-04-29
EP0610420A1 (de)	1994-08-17
AU679431B2 (en)	1997-07-03
DE69230943D1 (de)	2000-05-25
CA2120353A1 (en)	1993-04-29
ATE191928T1 (de)	2000-05-15

Publication	Publication Date	Title
US5928939A (en)	1999-07-27	Vascular endothelial growth factor-b and dna coding therefor
CA2387184C (en)	2014-02-11	Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8603967B2 (en)	2013-12-10	Carrier peptide fragment and use thereof
Keshav et al.	1995	Rpa4, a homolog of the 34-kilodalton subunit of the replication protein A complex
Inagaki et al.	1997	Phosphorylation-dependent control of structures of intermediate filaments: a novel approach using site-and phosphorylation state-specific antibodies
CA2130089A1 (en)	1993-09-16	Protein compound, coding nucleotide sequences, producing cell line and uses thereof
EP2480568B1 (de)	2016-04-20	Polypeptide und Nukleinsäuren zur Behandlung von ErbB2-abhängigen Krebserkrankungen
CN107629114B (zh)	2021-04-09	多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
NZ266162A (en)	1997-11-24	Dna encoding grb3-3 capable of inducing cell death and its use in anti-cancer gene therapy
EP0808323A1 (de)	1997-11-26	Mutanten der rb- und p53-gene und ihre verwendung
WO1996020207A9 (en)	1996-09-06	MUTANTS OF THE Rb AND p53 GENES AND USES THEREOF
JP7483227B2 (ja)	2024-05-15	Ｐｄ－１シグナル配列を有する抗腫瘍ペプチドおよびその利用
US20020115633A1 (en)	2002-08-22	Pharmaceutical composition containing ezrin mutated on tyrosin 353
EP0846761A1 (de)	1998-06-10	Ein neuer Transkriptionsfactor, der in Zellen, die sich im Zellzyklus befinden, exprimiert wird, Nukleinsäuremoleküle kodierend für diesen Transkriptionsfacktorund seine Promoterregion sowie dessen Verwendung
JP7329173B2 (ja)	2023-08-18	抗腫瘍ペプチドおよびその利用
US5955579A (en)	1999-09-21	Islet-specific homeoprotein and transcriptional regulator of insulin gene expression, HOXB13
CA2120353C (en)	2008-04-29	Cell cycle controlling compositions and methods of using same
US8088892B2 (en)	2012-01-03	Inhibitors of proteins from the Rho-GEF family
CA2447703C (en)	2011-04-19	Methods for proliferating terminal differentiated cells and recombinant vectors therefor
WO1995006661A1 (en)	1995-03-09	MUTANTS OF THE Rb AND p53 GENES AND USES THEREOF
US6200810B1 (en)	2001-03-13	Mutants of the Rb and p53 genes and uses thereof